Results 91 to 100 of about 837,658 (340)

Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases

The World Journal of Men's Health
Purpose: Finasteride and dutasteride are used to treat benign prostatic hyperplasia (BPH) and reduce the risk of developing prostate cancer. Finasteride blocks only the type 2 form of 5-alpha-reductase, whereas dutasteride blocks both type 1 and 2 forms
Dae Yul Yang, Won-Woo Seo, Rae Woong Park, Sang Youl Rhee, Jae Myung Cha, Yoon Soo Hah, Chang Won Jeong, Kyung-Jin Kim, Hyeon-Jong Yang, Do Kyung Kim, Ji Yong Ha   +10 more
doaj   +1 more source

The effect of cortisone and cortisol on 17-ketosteroid excretion in carcinoma of the prostate and other neoplasms [PDF]

, 1959
Joseph E. Sokal, K. W. Buchwald
openalex   +1 more source

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

FEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan, Bethany C. Guerra, Selina Uranga, Jessica M. Cardin, Steven E. Riechman, Mariana Janini Gomes, James D. Fluckey   +6 more
wiley   +1 more source

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL

International Brazilian Journal of Urology
Introduction: Prostate - specific antigen (PSA) is a useful biomarker for detection of prostate cancer (PCa) and for risk classification in addition to TNM classification and Gleason score (GS). We reported the role of PSA in patients with low (< 20 ng /
Hiroaki Iwamoto, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami   +3 more
doaj   +1 more source

Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies

Journal of Clinical Medicine
Prostate cancer liver metastasis (PCLM), seen in upwards of 25% of metastatic castration-resistant PC (mCRPC) patients, is the most lethal site of mCRPC with a median overall survival of 10–14 months. Despite its ominous prognosis and anticipated rise in
Audrey Shiner, R. Sperandio, M. Naimi, U. Emmenegger   +3 more
semanticscholar   +1 more source

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐NF1 patients and role of R1276

FEBS Open Bio, EarlyView.
Somatic variants of the neurofibromatosis type 1 (NF1) gene occur across neoplasms without clinical manifestation of the disease NF1. We identified emerging somatic pathogenic NF1 variants and hotspots, for example, at the arginine finger 1276. Those missense variants provide fundamental information about neurofibromin's role in cancer.
Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder   +7 more
wiley   +1 more source

Representation analysis of miRNA from clarified urine and urine microvesicles in prostate malignancies and non-malignant neoplasms [PDF]

, 2018
Ivan A. Zaporozhchenko, Olga E. Bryzgunova, Evgeniy A. Lekchnov, I.D. Osipov, M. M. Zaripov, Yu. B. Yurchenko, S. V. Yarmoschuk, Oxana A. Pashkovskaya, Elena Y. Rykova, А. А. Жеравин, Pavel P. Laktionov   +10 more
openalex   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Prospective evaluation of Chondroitin sulfate, Heparan sulfate and Hyaluronic acid in prostate cancer

International Brazilian Journal of Urology
Purpose: The present study evaluates chondroitin sulfate (CS) and heparan sulfate (HS) in the urine and hyaluronic acid (HA) in the plasma of patients with prostate cancer before and after treatment compared to a control group.
Matheus N. Ribeiro da Silva, Aline Mendes, João R. Maciel Martins, Marcos Tobias-Machado, Maria Aparecida da Silva Pinhal   +4 more
doaj   +1 more source

Oxidative stress and one carbon metabolism in prostate neoplasm [PDF]

, 2023
S. Kumari, J. Aggarwal, U. Midha, J. Batra, Nidhi Gupta Nidhi Gupta   +4 more
openalex   +1 more source